Cargando…

Generation of muscular dystrophy model rats with a CRISPR/Cas system

Duchenne muscular dystrophy (DMD) is an X-linked lethal muscle disorder caused by mutations in the Dmd gene encoding Dystrophin12. DMD model animals, such as mdx mice and canine X-linked muscular dystrophy dogs, have been widely utilized in the development of a treatment for DMD3. Here, we demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Katsuyuki, Fujii, Wataru, Tsuboi, Masaya, Tanihata, Jun, Teramoto, Naomi, Takeuchi, Shiho, Naito, Kunihiko, Yamanouchi, Keitaro, Nishihara, Masugi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088098/ https://www.ncbi.nlm.nih.gov/pubmed/25005781 http://dx.doi.org/10.1038/srep05635

Ejemplares similares

Cellular senescence-mediated exacerbation of Duchenne muscular dystrophy
por: Sugihara, Hidetoshi, et al.
Publicado: (2020)

Pathological evaluation of rats carrying in-frame mutations in the dystrophin gene: a new model of Becker muscular dystrophy
por: Teramoto, Naomi, et al.
Publicado: (2020)

Loss of p16/Ink4a drives high frequency of rhabdomyosarcoma in a rat model of Duchenne muscular dystrophy
por: TERAMOTO, Naomi, et al.
Publicado: (2021)

Secreted protein acidic and rich in cysteine internalization and its age-related alterations in skeletal muscle progenitor cells
por: Nakamura, Katsuyuki, et al.
Publicado: (2014)

Oxidative stress-mediated senescence in mesenchymal progenitor cells causes the loss of their fibro/adipogenic potential and abrogates myoblast fusion
por: Sugihara, Hidetoshi, et al.
Publicado: (2018)

Differentiation of skeletal muscle Mesenchymal progenitor cells to myofibroblasts is reversible
por: Takeuchi, Shiho, et al.
Publicado: (2020)

Reduced fibrillar collagen accumulation in skeletal muscle of secreted protein acidic and rich in cysteine (SPARC)-null mice
por: OMI, Sanae, et al.
Publicado: (2019)

Efficient mutagenesis by CRISPR/Cas system during meiotic maturation of porcine oocytes
por: ONUMA, Asuka, et al.
Publicado: (2016)

Efficient Generation of Genome-Modified Mice Using Campylobacter jejuni-Derived CRISPR/Cas
por: Fujii, Wataru, et al.
Publicado: (2017)

Applications of CRISPR/Cas9 for the Treatment of Duchenne Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2018)

Age-related resistance of skeletal muscle-derived progenitor cells to SPARC may explain a shift from myogenesis to adipogenesis
por: Nakamura, Serena Katsuyuki, et al.
Publicado: (2012)

Development of a mono-promoter-driven CRISPR/Cas9 system in mammalian cells
por: Yoshioka, Shin, et al.
Publicado: (2015)

One-step Generation of Phenotype-expressing Triple-knockout Mice with Heritable Mutated Alleles by the CRISPR/Cas9 System
por: FUJII, Wataru, et al.
Publicado: (2014)

A medium-chain triglyceride containing ketogenic diet exacerbates cardiomyopathy in a CRISPR/Cas9 gene-edited rat model with Duchenne muscular dystrophy
por: Fujikura, Yuri, et al.
Publicado: (2022)

Differential Roles of Cyclooxygenase-2-Related Signaling in Regulating Hypothalamic Neuronal Activity under Various Acute Stresses
por: MA, Yanbo, et al.
Publicado: (2013)

Free Access to Running Wheels Abolishes Hyperphagia in Human Growth Hormone Transgenic Rats
por: KOMATSUDA, Mugiko, et al.
Publicado: (2014)

Lack of estrogen receptor α in astrocytes of progranulin-deficient mice
por: DOKE, Mio, et al.
Publicado: (2016)

A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9
por: Sui, Tingting, et al.
Publicado: (2018)

CRISPR Therapeutics for Duchenne Muscular Dystrophy
por: Erkut, Esra, et al.
Publicado: (2022)

CRISPR-Cas9-mediated exon skipping as a cardioprotective strategy in Duchenne muscular dystrophy
por: Wilton-Clark, Harry, et al.
Publicado: (2023)

Progranulin deficiency leads to prolonged persistence of macrophages, accompanied with myofiber hypertrophy in regenerating muscle
por: SUGIHARA, Hidetoshi, et al.
Publicado: (2017)

CRISPR technologies for the treatment of Duchenne muscular dystrophy
por: Choi, Eunyoung, et al.
Publicado: (2021)

A new immunodeficient Duchenne muscular dystrophy rat model to evaluate engraftment after human cell transplantation
por: Sato, Masae, et al.
Publicado: (2023)

Possible involvement of lysosomal dysfunction in pathological changes of the brain in aged progranulin-deficient mice
por: Tanaka, Yoshinori, et al.
Publicado: (2014)

CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy
por: Lim, Kenji Rowel Q., et al.
Publicado: (2020)

Multiplex CRISPR/Cas9-Based Genome Editing for Correction of Dystrophin Mutations that Cause Duchenne Muscular Dystrophy
por: Ousterout, David G., et al.
Publicado: (2015)

CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells
por: Min, Yi-Li, et al.
Publicado: (2019)

Promising therapeutic approaches using CRISPR/Cas9 genome editing technology in the treatment of Duchenne muscular dystrophy
por: Mollanoori, Hasan, et al.
Publicado: (2020)

Efficient generation of large-scale genome-modified mice using gRNA and CAS9 endonuclease
por: Fujii, Wataru, et al.
Publicado: (2013)

Cellular Reprogramming, Genome Editing, and Alternative CRISPR Cas9 Technologies for Precise Gene Therapy of Duchenne Muscular Dystrophy
por: Gee, Peter, et al.
Publicado: (2017)

Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system
por: Zhang, Yu, et al.
Publicado: (2020)

Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening
por: Soblechero-Martín, Patricia, et al.
Publicado: (2021)

Characteristics of Japanese Patients with Becker Muscular Dystrophy and Intermediate Muscular Dystrophy in a Japanese National Registry of Muscular Dystrophy (Remudy): Heterogeneity and Clinical Variation
por: Mori-Yoshimura, Madoka, et al.
Publicado: (2018)

High-fidelity endonuclease variant HypaCas9 facilitates accurate allele-specific gene modification in mouse zygotes
por: Ikeda, Arisa, et al.
Publicado: (2019)

CRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities
por: Raaijmakers, Renée H.L., et al.
Publicado: (2019)

Macroglossia and less advanced dystrophic change in the tongue muscle of the Duchenne muscular dystrophy rat
por: Yamanouchi, Keitaro, et al.
Publicado: (2022)

Precise Correction of the Dystrophin Gene in Duchenne Muscular Dystrophy Patient Induced Pluripotent Stem Cells by TALEN and CRISPR-Cas9
por: Li, Hongmei Lisa, et al.
Publicado: (2014)

Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy
por: Bengtsson, Niclas E., et al.
Publicado: (2017)

CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy
por: Domenig, Seraina A., et al.
Publicado: (2022)

A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing
por: Zhang, Yu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t65aa6odhhih9917lndsil9c50